CN113248564B - Active peptide having tyrosinase inhibitory activity - Google Patents
Active peptide having tyrosinase inhibitory activity Download PDFInfo
- Publication number
- CN113248564B CN113248564B CN202110215490.7A CN202110215490A CN113248564B CN 113248564 B CN113248564 B CN 113248564B CN 202110215490 A CN202110215490 A CN 202110215490A CN 113248564 B CN113248564 B CN 113248564B
- Authority
- CN
- China
- Prior art keywords
- tyrosinase
- active peptide
- peptide
- activity
- inhibitory activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 51
- 102000003425 Tyrosinase Human genes 0.000 title claims abstract description 50
- 108060008724 Tyrosinase Proteins 0.000 title claims abstract description 50
- 230000002401 inhibitory effect Effects 0.000 title abstract description 16
- 230000000694 effects Effects 0.000 claims abstract description 20
- 230000005764 inhibitory process Effects 0.000 claims abstract description 11
- PUUYVMYCMIWHFE-BQBZGAKWSA-N Gly-Ala-Arg Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N PUUYVMYCMIWHFE-BQBZGAKWSA-N 0.000 claims abstract description 4
- QCVXMEHGFUMKCO-YUMQZZPRSA-N Asp-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC(O)=O QCVXMEHGFUMKCO-YUMQZZPRSA-N 0.000 claims abstract description 3
- NJSPTZXVPZDRCU-UBHSHLNASA-N Ser-Asp-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)N NJSPTZXVPZDRCU-UBHSHLNASA-N 0.000 claims abstract description 3
- 150000001413 amino acids Chemical group 0.000 claims abstract description 3
- 230000002087 whitening effect Effects 0.000 abstract description 9
- 208000003351 Melanosis Diseases 0.000 abstract description 8
- 239000002537 cosmetic Substances 0.000 abstract description 8
- 206010008570 Chloasma Diseases 0.000 abstract description 7
- 230000008099 melanin synthesis Effects 0.000 abstract description 3
- 231100000956 nontoxicity Toxicity 0.000 abstract description 3
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 230000029087 digestion Effects 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 19
- 238000006243 chemical reaction Methods 0.000 description 13
- 238000002835 absorbance Methods 0.000 description 10
- 239000003112 inhibitor Substances 0.000 description 8
- 238000012216 screening Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 6
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 6
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 6
- 238000006911 enzymatic reaction Methods 0.000 description 5
- 238000003032 molecular docking Methods 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 230000000975 bioactive effect Effects 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 101710147108 Tyrosinase inhibitor Proteins 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- VNXWANZMRATDQM-UHFFFAOYSA-N 2-(2-phenylethyl)benzene-1,3-diol Chemical compound OC1=CC=CC(O)=C1CCC1=CC=CC=C1 VNXWANZMRATDQM-UHFFFAOYSA-N 0.000 description 2
- 230000035495 ADMET Effects 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- 208000012641 Pigmentation disease Diseases 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 238000010535 acyclic diene metathesis reaction Methods 0.000 description 2
- 229960000271 arbutin Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000001976 enzyme digestion Methods 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 2
- 229960004705 kojic acid Drugs 0.000 description 2
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 102000030523 Catechol oxidase Human genes 0.000 description 1
- 108010031396 Catechol oxidase Proteins 0.000 description 1
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000007854 depigmenting agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000005171 mammalian brain Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000036211 photosensitivity Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0819—Tripeptides with the first amino acid being acidic
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Cosmetics (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention discloses an active peptide with tyrosinase inhibition effect, and the amino acid sequences of the active peptide are Ser-Asp-Trp (SDW), Gly-Ala-Arg (GAR) and Asp-Gly-Leu (DGL). The active peptide with the tyrosinase inhibiting effect can continuously and stably inhibit the activity of tyrosinase and inhibit the synthesis of melanin, has the advantages of high activity, safety, no toxicity, easy digestion and absorption and the like, can be used as a whitening functional component for cosmetics and health-care products which are beneficial to improving the chloasma function, and has wide application prospect and very important significance.
Description
Technical Field
The invention belongs to the field of bioactive peptides, and particularly relates to a bioactive peptide with tyrosinase inhibition effect.
Background
Tyrosinase (ec1.14.18.1), also known as polyphenol oxidase, is a key rate-limiting enzyme that catalyzes melanin synthesis, which is widely present in the body. During melanin production, tyrosinase catalyzes the oxidation of L-tyrosine to L-dopa, which is subsequently oxidized to L-dopaquinone, which is then converted to melanin by a series of non-enzymatic reactions. In the human body, tyrosinase is overexpressed, which may cause pigmentation diseases such as age spots, freckles, chloasma, melanoma, and the like. Among them, chloasma is the most common pigmentation disease, often occurs on female face, and seriously affects appearance. At present, no effective means for treating chloasma exists, emotional problems and psychological stress are caused to patients, and the quality of life is reduced. Meanwhile, tyrosinase activity has been found to be associated with parkinson's disease and other neurodegenerative diseases in the mammalian brain.
Researches find that the generation of skin melanin can be reduced by inhibiting the activity of tyrosinase, and the tyrosinase inhibitor has wide application prospects in the fields of cosmetics, health-care products and medicines. At present, common tyrosinase inhibitors mainly comprise kojic acid, ascorbic acid, arbutin and the like. The whitening cosmetic containing the tyrosinase inhibitor has a whitening effect on skin and can cause certain damage to the skin, and the inhibitor is easy to cause product instability. For example, kojic acid is widely used for treating melanodermopathy, but it has poor stability and can cause skin cancer in long-term use. Ascorbic acid is a widely used skin whitening agent, but fails to work rapidly by undergoing redox reactions. Arbutin has high photosensitivity and instability, and is easy to discolor when added into whitening cosmetics. The Chinese invention patent discloses a composition with a synergistic tyrosinase inhibition effect and an application (publication No. CN 111920790A, application date 2020.09.15), wherein the composition with the synergistic tyrosinase inhibition effect takes phenethyl resorcinol as an effective component, and the skin is affected by the use of the phenethyl resorcinol in an overdose manner. Therefore, the search for a novel tyrosinase inhibitor which is natural, nontoxic, stable and efficient is of great significance. The active peptide is natural, safe, efficient and easy to be absorbed by human body, and has good skin whitening effect.
The invention aims to provide an active peptide with tyrosinase inhibition effect, and the active peptide is applied to the preparation of health care products and whitening cosmetics which are helpful for improving chloasma.
Disclosure of Invention
The invention discloses an active peptide with tyrosinase inhibition effect, and the amino acid sequences of the active peptide are Ser-Asp-Trp, Gly-Ala-Arg and Asp-Gly-Leu respectively.
The active peptide with tyrosinase inhibition effect can be used for preparing health care products and whitening cosmetics which are helpful for improving chloasma.
The active peptide with tyrosinase inhibition effect has the butt-joint energy values of-84.32, -81.67, -112.12kcal mol-1semi-Inhibitory Concentration (IC) on tyrosinase Activity50) 0.84mg/mL, 0.34mg/mL, and 0.15mg/mL, respectively.
The purpose of the invention is realized by the following technical scheme:
(1) screening of active peptides
The invention carries out virtual enzyme digestion on a collagen sequence by means of an online enzyme digestion tool ExPASY Peptidecutter (http:// web. expask. org/peptide _ cutter /), and totally releases 111 peptide sequences. The biological activity, water solubility and toxicity of the obtained peptide sequence are predicted by ADMET modules of an online program PeptideRanker, peptide property calculator and Discovery Studio (DS), and 25 bioactive peptides with good biological activity, water solubility and no toxicity are obtained by screening. The 3D structure of tyrosinase (PDB ID: 2Y9X) was obtained from Protein Data Bank (PDB) database and used as receptor Protein, and DS software was used to perform molecular docking screening of peptides capable of binding tightly to tyrosinase active site. The 'CDOCKER _ Energy' value is taken as a screening index to obtain three peptides SDW, GAR and DGL which have the most potential tyrosinase inhibitory activity.
(2) In vitro tyrosinase inhibitory Activity assay
The inhibitory activity of the peptides SDW, GAR, and DGL on tyrosinase was determined spectrophotometrically. Taking peptide solutions with different concentrations, adding tyrosinase, incubating at 25 ℃ for 5min, adding L-dopa solution, reacting for 5min, and immediately determining the absorbance value of the reaction solution at 475nm after the reaction is finished.
The tyrosinase inhibition rates were calculated for different concentrations of peptide using the following formula:
tyrosinase inhibitory activity (%) [ (A-B) - (C-D) ]. times.100/(A-B)
Wherein A is an absorbance value of a reaction solution containing no inhibitor, B is an absorbance value of a reaction solution containing no inhibitor and an enzyme reaction solution, C is an absorbance value of a reaction solution containing L-dopa, and D is an absorbance value of a reaction solution containing no enzyme reaction solution. IC (integrated circuit)50Defined as the concentration of inhibitor that inhibits 50% of tyrosinase activity under the assay conditions.
Compared with the prior art, the invention has the following beneficial effects:
the invention screens and obtains the peptides SDW, GAR and DGL which can effectively inhibit the activity of tyrosinase from collagen, and defines the molecular action mechanism of active peptide and the active site of tyrosinase. The active peptides SDW, GAR and DGL can effectively inhibit the activity of tyrosinase and the generation of melanin, so that the active peptides SDW, GAR and DGL can be used as whitening functional components for cosmetics and health care products, and have good application prospects.
Drawings
The invention is illustrated in figure 1, wherein:
FIG. 1 shows the molecular docking results 2D of DGL with tyrosinase;
Detailed Description
The invention will now be further illustrated by means of specific examples
Example 1 screening of active peptides having tyrosinase inhibitory Activity
The invention selects pepsin (EC 3.4.23.1) and trypsin (EC 3.4.21.4) in an online enzyme digestion website ExPASY peptide cutter (http:// web. ExPASy. org/peptide _ cutter /) to carry out virtual enzymolysis on collagen, thereby obtaining 111 peptide sequences. The ADMET modules of an online tool PeptideRanker, peptide property calculator and Discovery Studio are used for respectively predicting the biological activity, water solubility and toxicity of the obtained peptide sequences, and 25 bioactive peptides with the biological activity scores higher than 0.5, good water solubility and no toxicity are obtained by screening, and are shown in Table 1.
Table 1 bioactivity, water solubility, toxicity prediction and molecular docking results for peptides
The crystal structure of tyrosinase (PDB ID: 2Y9X) was obtained from the PDB database, with the removal of water molecules, hydrogen atoms and definition of the acceptor protein, with the active neutral coordinate x: -10.044, y: -28.706, z: -43.443. The active peptide 3D structure was mapped with DS software, energy minimized using minize Ligands module, and as small molecule ligand. Molecular docking was performed by the CDOCKER program in DS to evaluate how tightly the active peptide binds to tyrosinase. Three polypeptides SDW, GAR and DGL with the most potential tyrosinase inhibitory activity are obtained by screening according to the docking score '-CDOCKER _ Energy' value and are shown in Table 1. The results indicate that all three active peptides bind to the tyrosinase residues His85, His244, His259, and Asn260, and that hydrogen bonding and van der waals interactions are the primary forces for peptide binding to tyrosinase.
Example 2 identification of tyrosinase inhibitory Activity in vitro of the peptides SDW, GAR and DGL
The inhibitory activity of tyrosinase on the active peptides SDW, GAR and DGL was determined by spectrophotometry. 60 μ L of peptide solutions of different concentrations were added to 40 μ L (500U/mL) of tyrosinase solution and incubated at 25 ℃ for 5 min. The reaction was then started by adding 200. mu. L L-dopa solution (0.5mM), and the absorbance at 475nm of the reaction solution was measured immediately after completion of the reaction at 25 ℃ for 5 min.
The tyrosinase inhibition rates were calculated for different concentrations of peptide using the following formula:
tyrosinase inhibitory activity (%) [ (A-B) - (C-D) ]. times.100/(A-B)
Wherein A is an absorbance value of a reaction solution containing no inhibitor, B is an absorbance value of a reaction solution containing no inhibitor and an enzyme reaction solution, C is an absorbance value of a reaction solution containing L-dopa, and D is an absorbance value of a reaction solution containing no enzyme reaction solution. IC (integrated circuit)50Defined as the concentration of inhibitor that inhibits 50% of tyrosinase activity under the assay conditions.
Tyrosinase activity definition: the amount of enzyme required to catalyze the production of 1moL of dopaquinone from L-dopa at 25 ℃ is defined as one unit (U) of tyrosinase activity.
The results indicate that the peptides SDW, GAR and DGL are all effective in inhibiting tyrosinase activity, its IC50The values were 0.84mg/mL, 0.34mg/mL, and 0.15mg/mL, respectively.
Example 3 use of the tyrosinase inhibiting peptides SDW, GAR, DGL
In the actual production, the tyrosinase inhibitory peptides SDW, GAR and DGL can be obtained by solid phase synthesis or directed biological enzymolysis and purification, and are prepared into granular, powder or liquid dissolved in water to be added into health products, which is helpful for improving chloasma on human faces. The active peptide can also be added into conventional facial cleanser, facial mask and cream to prepare whitening cosmetics.
The technical solutions of the present invention are described in detail in the embodiments described above, it should be understood that the above are only specific embodiments of the present invention, and are not intended to limit the present invention, and it should be noted that: it will be apparent to those skilled in the art that various changes and modifications may be made without departing from the spirit and scope of the invention, and these changes and modifications should also be considered as within the scope of the invention.
Claims (1)
1. The amino acid sequence of the active peptide with the tyrosinase inhibition effect is Ser-Asp-Trp or Gly-Ala-Arg or Asp-Gly-Leu.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110215490.7A CN113248564B (en) | 2021-02-10 | 2021-02-10 | Active peptide having tyrosinase inhibitory activity |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110215490.7A CN113248564B (en) | 2021-02-10 | 2021-02-10 | Active peptide having tyrosinase inhibitory activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113248564A CN113248564A (en) | 2021-08-13 |
| CN113248564B true CN113248564B (en) | 2022-02-11 |
Family
ID=77180975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110215490.7A Expired - Fee Related CN113248564B (en) | 2021-02-10 | 2021-02-10 | Active peptide having tyrosinase inhibitory activity |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113248564B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115353548B (en) * | 2022-09-20 | 2024-03-15 | 华南农业大学 | Pearl shell tyrosinase inhibitory peptide with whitening effect and application thereof |
| CN115477686B (en) * | 2022-09-22 | 2024-01-30 | 北海黑珍珠海洋生物科技有限公司 | Pearl shell active peptide with whitening effect and application thereof |
| CN117106015B (en) * | 2023-09-01 | 2024-04-26 | 海南大学 | Coconut-derived active peptide and application thereof |
| CN117106016A (en) * | 2023-09-01 | 2023-11-24 | 海南大学 | Donkey-hide gelatin source tyrosinase inhibitory peptide and application thereof |
| CN118005729A (en) * | 2024-02-27 | 2024-05-10 | 中国农业大学 | Polypeptide with tyrosinase inhibitory activity and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108379550A (en) * | 2018-05-31 | 2018-08-10 | 吉林大学 | A kind of Corn source monomeric peptide is as the application in tyrosinase inhibitor |
| CN110218240A (en) * | 2019-06-14 | 2019-09-10 | 河北黄金龙农业科技有限公司 | A kind of tyrosinase peptide for inhibiting and its application |
-
2021
- 2021-02-10 CN CN202110215490.7A patent/CN113248564B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108379550A (en) * | 2018-05-31 | 2018-08-10 | 吉林大学 | A kind of Corn source monomeric peptide is as the application in tyrosinase inhibitor |
| CN110218240A (en) * | 2019-06-14 | 2019-09-10 | 河北黄金龙农业科技有限公司 | A kind of tyrosinase peptide for inhibiting and its application |
Non-Patent Citations (1)
| Title |
|---|
| 酪氨酸酶抑制剂的研究进展;陈清西等;《厦门大学学报(自然科学版)》;20070330(第02期);全文 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113248564A (en) | 2021-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113248564B (en) | Active peptide having tyrosinase inhibitory activity | |
| Li et al. | Recent advances in the design and discovery of synthetic tyrosinase inhibitors | |
| Wang et al. | Role of vitamin C in skin diseases | |
| Ha et al. | Analogs of 5-(substituted benzylidene) hydantoin as inhibitors of tyrosinase and melanin formation | |
| CN105362088B (en) | A kind of peptide composition for the light spot of whitening skin lightening | |
| CN100428939C (en) | Composition for external use | |
| TWI480057B (en) | Use of caffeamide derivative | |
| JP7233556B2 (en) | Use of Salidroside Derivatives in Skin Whitening Topical Preparations | |
| Takata et al. | Catalytic Mechanism ofS-Adenosylhomocysteine Hydrolase: SITE-DIRECTED MUTAGENESIS OF ASP-130, LYS-185, ASP-189, AND ASN-190 | |
| Best et al. | Multiple skin cancers associated with hydroxyurea therapy | |
| CN113520898B (en) | Application of hirulog HE-D in skin care and whitening | |
| Yun et al. | Design, synthesis, and anti-melanogenic effects of (E)-2-benzoyl-3-(substituted phenyl) acrylonitriles | |
| CN100484509C (en) | Use of C-glycosides for depigmenting skin | |
| CN107266534A (en) | The anti-oxidant small peptide for suppressing melanin generation, preparation method and applications | |
| CN109797133A (en) | Multipotential cell culture composition and preparation method and application | |
| CN103468774B (en) | Method for separating alpha-glucosidase inhibitor from laver enzymolysis product | |
| JP2003221307A (en) | Agent for inhibiting formation of melanin | |
| Hwang et al. | Catechin-7-O-α-L-rhamnopyranoside can reduce α-MSH-induced melanogenesis in B16F10 melanoma cells through competitive inhibition of tyrosinase | |
| CN104905985B (en) | Application of the laurate modification SOD in cosmetics | |
| JP2018165266A (en) | Peeling gel using basic aqueous solution | |
| Chandarajoti et al. | Synthesis and evaluation of coumarin derivatives on antioxidative, tyrosinase inhibitory activities, melanogenesis, and in silico investigations | |
| CN117106015B (en) | Coconut-derived active peptide and application thereof | |
| Im et al. | In vitro screening of extracts from 38 marine animal resources for novel cosmeceutical activities | |
| Ghofrani et al. | New insight into the interactions of arbutin with mushroom tyrosinase | |
| EP3279184B1 (en) | Novel benzoic acid amide compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20220211 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |